Security
IDXG · INTERPACE BIOSCIENCES, INC.
IDXGOTCCommon stockHistorical · closed Jun 21, 2022CIK 1054102Updated Sep 25, 2026
Name history
Interpace Diagnostics Group, Inc. · through Nov 1, 2019PDI INC · through Dec 22, 2015PROFESSIONAL DETAILING INC · through Nov 13, 2002
Current security for this SEC filerIDXGD · OTC
IDXG price & chart
Historical security
This listing closed Jun 21, 2022. Live provider charts are shown only for current listings.
Current security: IDXGD
About the company
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.
In the news
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results ↗
Recent filings
S-1 filing
S-8 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 5.03, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 33,838,000Source | 12,142,000Source | 13,021,000Source | 15,979,000Source |
| Property, Plant and Equipment, NetUSD | 1,423,000Source | 925,000Source | 790,000Source | 480,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,505,000Source | 2,812,000Source | 3,498,000Source | 4,828,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,649,000Source | 5,006,000Source | 4,983,000Source | 5,032,000Source |
| Inventory, NetUSD | 1,114,000Source | — | 1,227,000Source | 1,224,000Source |
| Assets, CurrentUSD | 9,900,000Source | 9,416,000Source | 10,322,000Source | 12,154,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,217,000Source | 1,756,000Source | 1,864,000Source | 2,439,000Source |
| Other Assets, NoncurrentUSD | 44,000Source | 45,000Source | 45,000Source | 45,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,475,000Source | 20,374,000Source | 28,157,000Source | 32,515,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 407,000Source | 406,000Source | 405,000Source | 405,000Source |
| Retained Earnings (Accumulated Deficit)USD | -210,805,000Source | -241,374,000Source | -248,215,000Source | -249,017,000Source |
| Stockholders' Equity Attributable to ParentUSD | 22,363,000Source | -54,768,000Source | -61,672,000Source | -63,072,000Source |
| Additional Paid in Capital, Common StockUSD | 234,833,000Source | 188,224,000Source | 188,146,000Source | 187,516,000Source |
| Liabilities and EquityUSD | 33,838,000Source | 12,142,000Source | 13,021,000Source | 15,979,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,103,000Source | 12,600,000Source | 17,474,000Source | 14,283,000Source |
| Operating Lease, Liability, CurrentUSD | 431,000Source | — | 377,000Source | 578,000Source |
| Accounts Payable, CurrentUSD | 983,000Source | 1,363,000Source | 1,544,000Source | 1,050,000Source |
| Operating Lease, Liability, NoncurrentUSD | 752,000Source | 1,359,000Source | 1,472,000Source | 1,848,000Source |
| Other Liabilities, NoncurrentUSD | 5,620,000Source | 5,072,000Source | 4,968,000Source | 4,701,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 425,000Source | 300,000Source | 1,026,000Source | 2,560,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 35,000Source | 291,000Source | 630,000Source | 1,258,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -2,895,000Source | 3,466,000Source | -49,000Source | 133,000Source |
| Increase (Decrease) in Accounts PayableUSD | -807,000Source | 120,000Source | 489,000Source | -735,000Source |
| Deferred Income Tax Expense (Benefit)USD | -21,254,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 5,831,000Source | 4,646,000Source | 3,789,000Source | -7,692,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -356,000Source | -876,000Source | -87,000Source | 6,206,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 356,000Source | 876,000Source | 470,000Source | 322,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -4,431,000Source | -5,807,000Source | -5,032,000Source | 3,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,044,000Source | -2,037,000Source | -1,330,000Source | 1,514,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,505,000Source | 1,461,000Source | 3,498,000Source | 4,828,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 168,000Source | 625,000Source | 1,092,000Source | 971,000Source |
| Income Taxes Paid, NetUSD | 101,000Source | 274,000Source | 270,000Source | 251,000Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | 34,000Source | — | — |
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | — | 112,000Source | 158,000Source |
| AmortizationUSD | — | — | 861,000Source | 1,270,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 35,000Source | 291,000Source | 630,000Source | 1,191,000Source |
| Amortization of Debt Issuance CostsUSD | 58,000Source | — | 42,000Source | 60,000Source |
| Amortization of Intangible AssetsUSD | — | — | 900,000Source | 1,300,000Source |
| General and Administrative ExpenseUSD | 9,480,000Source | 9,486,000Source | 9,363,000Source | 10,973,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 8,433,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 3,964,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 4,100,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 24,984,000Source | 6,946,000Source | 1,112,000Source | -5,865,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -409,000Source | -244,000Source | -310,000Source | -16,093,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 8,100,000Source | 2,800,000Source | — |
| Income Tax Expense (Benefit)USD | -21,210,000Source | 4,000Source | 17,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | 24,575,000Source | 6,702,000Source | 802,000Source | -21,958,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 24,575,000Source | 6,238,000Source | — | — |
| Operating ExpensesUSD | 20,046,000Source | 21,817,000Source | 21,100,000Source | 21,848,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 700,000Source | 800,000Source | 900,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -667,000Source | -1,211,000Source |
| Other Operating Income (Expense), NetUSD | -142,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 108,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 38,728,000Source | 46,926,000Source | 40,214,000Source | 31,838,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | 4,084,000Source | 8,108,000Source | 2,804,000Source | -3,617,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -667,000Source | -1,211,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 3,774,000Source | 6,950,000Source | 1,129,000Source | -5,836,000Source |
| Income Tax Expense (Benefit)USD | -21,210,000Source | 4,000Source | 17,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | 24,575,000Source | 6,702,000Source | 802,000Source | -21,958,000Source |
| Earnings Per Share, BasicUSD per share | 5.55Source | 1.42Source | 0.19Source | -5.18Source |
| Earnings Per Share, DilutedUSD per share | 0.89Source | 0.4Source | 0.18Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,424,000Source | 4,387,000Source | 4,317,000Source | 4,238,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,695,000Source | 15,734,000Source | 4,364,000Source | 4,238,000Source |
| Additional Financial Items | ||||
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | — | 112,000Source | 158,000Source |
| Amortization of Intangible AssetsUSD | — | — | 900,000Source | 1,300,000Source |
| Current Income Tax Expense (Benefit)USD | 44,000Source | 4,000Source | 17,000Source | 29,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 200,000Source | 200,000Source |
| General and Administrative ExpenseUSD | 9,480,000Source | 9,486,000Source | 9,363,000Source | 10,973,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 8,433,000Source |
| Gross ProfitUSD | 24,130,000Source | 29,925,000Source | 23,904,000Source | 18,231,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 4,100,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 24,984,000Source | 6,946,000Source | 1,112,000Source | -5,865,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | 5.65Source | 1.48Source | 0.26Source | -1.38Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | 0.9Source | 0.41Source | 0.25Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -409,000Source | -244,000Source | -310,000Source | -16,093,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 8,100,000Source | 2,800,000Source | — |
| Interest Income (Expense), NetUSD | — | — | -112,000Source | -158,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 24,575,000Source | 6,238,000Source | — | — |
| Operating ExpensesUSD | 20,046,000Source | 21,817,000Source | 21,100,000Source | 21,848,000Source |
| Operating Lease, ExpenseUSD | 600,000Source | 700,000Source | 800,000Source | 900,000Source |
| Other Operating Income (Expense), NetUSD | -142,000Source | — | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | 464,000Source | — | — |
| Research and Development ExpenseUSD | 642,000Source | 676,000Source | 636,000Source | 703,000Source |
| Selling and Marketing ExpenseUSD | 9,924,000Source | 11,655,000Source | 10,233,000Source | 9,125,000Source |
Offerings
Registration 333-299123
Filing attachments
ex107.htm · S-1 · 2026-09-25
Calculation of Filing Fee Tables S-1 INTERPACE BIOSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-27
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting PARSIPPANY, NJ, August 26, 2026 - Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-for-5 reverse stock split (“Reverse Stock Split”) of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results Q2 Revenue of $9.1 million Q2 Income from Continuing Operations of $0.3 million Q2 Thyroid volume year-over-year increase of 6% Q2 Thyroid revenue year-over-year increase of 9% Trailing twelve-month thyroid revenue of $36.1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, August 10, 2026 (GLOBE NEWSWIRE) - Interpac…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces First Quarter 2026 Financial and Business Results Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quart…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-01
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results Q4 and FY Revenue of $9.2 million and $38.7 million Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) Q4 and FY Thyroid volume year-over-year increase of 11% and 13% Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PAR…
Read attachment ↗ex99-1.htm · 8-K · 2026-01-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net Income and EBITDA operations Company to seek uplisting on the Nasdaq Stock Market PARSIPPANY, NJ, Jan. 20, 2026…
Read attachment ↗